SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
May 3, 2004
Date of Report (Date of Earliest Event Reported)
Schering-Plough Corporation
(Exact name of registrant as specified in its charter)
New Jersey 1-6571 22-1918501
(State or other jurisdiction (Commission File Number) (IRS Employer
of incorporation) Identification Number)
2000 Galloping Hill Road
Kenilworth, NJ 07033
(Address of principal executive offices, including Zip Code)
(908) 298-4000
(Registrant's telephone number, including area code)
Item 7. Financial Statements and Exhibits
(c) Exhibit. The following exhibit is filed with this 8-K:
99.1 May 3, 2004 Press Release Titled "Schering-Plough Reaches Agreement With
Texas Attorney General's Office"
Item 9. Regulation FD Disclosure
On May 3, 2004 Schering-Plough announced that it has reached an agreement with
the attorney general's office of the State of Texas to settle issues related to
reimbursement by Texas' medicaid program of albuterol sulfate solution and
inhaler products. These are asthma products sold by Warrick Pharmaceuticals,
Schering-Plough's generic subsidiary. Under the agreement, Schering-Plough has
agreed to pay $27 million to the State of Texas. A press release relating to the
settlement is attached to this 8-K as Exhibit 99.2.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
Schering-Plough Corporation
By:/s/ Thomas H.Kelly
--------------------
Thomas H. Kelly
Vice President and Controller
Date: May 5, 2004
Exhibit Index
The following exhibit is filed with this 8-K:
99.1 May 3, 2004 Press Release Titled "Schering-Plough Reaches Agreement With
Texas Attorney General's Office"